As Wealthy Get Dengue Fever, Drug Companies More Likely to Act (Asia)
This article was originally published in PharmAsia News
Executive Summary
A recent report has found that rates of dengue infection are on the rise. Singapore has reported over 5,000 infections while India has over 100,000 recorded, including over 1,000 deaths. Recorded in the journal Nature, the report notes that infection rates are becoming particularly prevalent in wealthy and middle class Asian communities. Advocates for a dengue vaccine hope this trend will encourage major pharmaceutical companies to consider developing better preventative treatments. Their involvement would be essential since developing the vaccine is likely to be a costly proposition. Experts note any vaccine would have to be capable of addressing at least four strains of the virus to prove effective. (Click here for more
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.